JPH045649B2 - - Google Patents
Info
- Publication number
- JPH045649B2 JPH045649B2 JP61309240A JP30924086A JPH045649B2 JP H045649 B2 JPH045649 B2 JP H045649B2 JP 61309240 A JP61309240 A JP 61309240A JP 30924086 A JP30924086 A JP 30924086A JP H045649 B2 JPH045649 B2 JP H045649B2
- Authority
- JP
- Japan
- Prior art keywords
- hemicellulose
- intestinal
- bifidobacterium
- bacteria
- rice bran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920002488 Hemicellulose Polymers 0.000 claims description 24
- 230000000968 intestinal effect Effects 0.000 claims description 21
- 235000007164 Oryza sativa Nutrition 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 235000009566 rice Nutrition 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 235000015099 wheat brans Nutrition 0.000 claims description 4
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 239000010903 husk Substances 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 241000186000 Bifidobacterium Species 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 13
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 241000209094 Oryza Species 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003636 fecal output Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
産業上の利用分野
本発明は、ヘミセルロースＢを有効成分とする
整腸剤に関する。本発明に係るヘミセルロースＢ
は、腸内細菌として有益なビフイドバクテリウム
菌に発酵されるため、ビフイドバクテリウム菌の
腸内増殖を促進して整腸作用をするものと考え
る。
技術的背景
セルロース、ヘミセルロース、水溶性及び不溶
性ペクチン質、リグニン、キチン、粘質物（ガラ
クトマンナン、グルコマンナンなど）、海藻多糖
質、化学修飾多糖類（化工澱粉、カルボキシメチ
ルセルロース）等は、食物繊維（ダイエタリー・
フアイバー）又は食餌性繊維と称せられ、ヒトの
消化酵素により消化されない食物中の難消化性成
分であるが、近年、それの摂取が有益な生理作用
を示すことから注目されてきている。
すなわち、これらの食物繊維を摂取すると、
腸の活動を高め、食物の腸内通過時間を短縮して
有害物質の吸収を阻害する、腸内容量及び糞便
量を増大する。コレステロール、胆汗酸、重金
属を吸着して排泄する、腸内菌のバランスを有
用菌優位として無害化する、等の生理上の効果が
あると報告されている。
一方、ビフイドバクテリウム菌はヒトの腸管内
に生育し、腸内のPHを低下させることにより、腐
敗性細菌の増殖に対して拮抗的作用を示して腐敗
生成物の生成を抑制する等生理的に有用な菌種で
あることが知られている。
本発明者は、上記食物繊維に含まれる水溶性多
糖類の腸内細菌に対する発酵性を検討した結果、
水溶性多糖類はビフイドバクテリウム菌に選択的
に発酵され、一方腐敗性細菌に発酵されないこと
を見出し、本発明をなすに至つた。
発明が解決しようとする課題
本発明は、腸内有用菌であるビフイドバクテリ
ウム菌に選択的に発酵されるヘミセルロースＢを
有効成分とする整腸剤を提供することを課題とす
る。
以下本発明を詳しく説明する。
発明の構成
本発明の特徴は、ヘミセルロースＢを有効成分
とする整腸剤にある。すなわち、ヘミセルロース
Ｂの摂取により腸内細菌であるビフイドバクテリ
ウム菌の増殖を促進することにより、該多糖類自
体の生理的作用とビフイドバクテリウム菌の生理
的作用により整腸効果を示すものである。
課題を解決するための手段
本発明で有効成分として利用するヘミセルロー
スＢは、米糠、小麦麸またはトウモロコシ外皮等
の殻物精選に際して得られる副生物をｎ−ヘキサ
ンのような有機溶媒で脱脂処理した後、水酸化ナ
トリウム溶液を加えて窒素ガスで置換した容器内
で抽出する。この抽出液から遠心分離等の操作に
より残渣を除去し、中和した後、イオン交換樹脂
により除蛋白した上清に、適宜脱塩処理を行つた
後、エタノールを加えるとヘミセルロースＢの沈
澱物が得られ、この沈澱物を適宜乾燥するとヘミ
セルロースＢの粉末が得られる。
このようにして得られるヘミセルロースＢ粉末
は、無味であつて、水溶性であるため、タブレツ
ト形態、ドリンク剤形態として摂取することがで
き、また、そのまま食物に混合して摂取してもよ
い。
なお、このヘミセルロースＢはアラビノースと
キシロースが結合した形態の多糖である。次に、
脱脂米糠及び小麦麸由来の水溶性多糖類の成分組
成を表１に示す。
INDUSTRIAL APPLICATION FIELD The present invention relates to an intestinal regulating agent containing hemicellulose B as an active ingredient. Hemicellulose B according to the present invention
Since it is fermented by Bifidobacterium, which is beneficial as an intestinal bacterium, it is thought that it promotes the intestinal proliferation of Bifidobacterium and has an intestinal regulating effect. Technical background Cellulose, hemicellulose, water-soluble and insoluble pectin substances, lignin, chitin, mucilage substances (galactomannan, glucomannan, etc.), seaweed polysaccharides, chemically modified polysaccharides (modified starch, carboxymethyl cellulose), etc. are dietary fibers ( Dietary・
Dietary fiber is an indigestible component of food that is not digested by human digestive enzymes, and has recently attracted attention because its ingestion exhibits beneficial physiological effects. In other words, when you ingest these dietary fibers,
Increases intestinal capacity and fecal volume, increasing intestinal activity, shortening the intestinal transit time of food and inhibiting the absorption of harmful substances. It has been reported that it has physiological effects such as adsorbing and excreting cholesterol, bile sweat acid, and heavy metals, and rendering the intestinal bacteria harmless by favoring beneficial bacteria. On the other hand, Bifidobacterium grows in the human intestinal tract, and by lowering the pH in the intestine, it exhibits an antagonistic effect on the growth of putrefactive bacteria and inhibits the production of putrefactive products. It is known to be a useful bacterial species. As a result of examining the fermentability of water-soluble polysaccharides contained in the above-mentioned dietary fibers to intestinal bacteria, the present inventor found that
It was discovered that water-soluble polysaccharides are selectively fermented by Bifidobacterium, but not by putrefactive bacteria, leading to the present invention. Problems to be Solved by the Invention An object of the present invention is to provide an intestinal regulating agent containing hemicellulose B as an active ingredient, which is selectively fermented by Bifidobacterium, which is a beneficial intestinal bacterium. The present invention will be explained in detail below. Structure of the Invention The present invention is characterized by an intestinal regulating agent containing hemicellulose B as an active ingredient. That is, by ingesting hemicellulose B, it promotes the growth of Bifidobacterium, which is an intestinal bacterium, and thereby exhibits an intestinal regulating effect due to the physiological action of the polysaccharide itself and the physiological action of Bifidobacterium. It is. Means for Solving the Problems Hemicellulose B used as an active ingredient in the present invention is obtained by degreasing a by-product obtained during the selection of shell materials such as rice bran, wheat bran or corn husk with an organic solvent such as n-hexane. , add sodium hydroxide solution and extract in a container purged with nitrogen gas. After removing the residue from this extract by operations such as centrifugation and neutralizing it, the supernatant was deproteinized using an ion exchange resin, desalted as appropriate, and ethanol was added to remove the hemicellulose B precipitate. When this precipitate is appropriately dried, a powder of hemicellulose B is obtained. Since the hemicellulose B powder thus obtained is tasteless and water-soluble, it can be taken in the form of a tablet or drink, or it can be mixed with food and taken as is. Note that this hemicellulose B is a polysaccharide in the form of arabinose and xylose bonded together. next,
Table 1 shows the composition of water-soluble polysaccharides derived from defatted rice bran and wheat bran.
【表】
次に、上記ヘミセルロースＢ粉末の腸内細菌に
対する発酵性試験を行つた結果を示す。腸内細菌
に対する発酵性試験
試験方法：
ヒト由来のストレプトコツカス属、ラクトバチ
ルス属、ビフイドバクテリウム属、クロストリジ
ウム属、スタフイロコツカス属、及びバクテロイ
デス属に属する菌株を用いて行つた。
培地は、バクテロイデス属にPYF液体培地を
用い、それぞれに水溶性多糖類0.25％を無菌的に
添加して用いた。その培地に各菌体懸濁液を菌数
が105〜106個となるように接種し、嫌気的に48時
間培養した。一方、対照としてグルコース0.5％
添加培地、また盲検として糖類無添加培地を用
い、同様に各菌体を培養した。
各菌体の発酵性は、グルコース培養液の660nm
における吸光度の値から盲検値を差し引いた値を
100とし、各培養液の660nmにおける吸光度の値
から盲検値を差し引いた値を換算して表した。[Table] Next, the results of a fermentability test of the hemicellulose B powder against intestinal bacteria are shown. Fermentability test on intestinal bacteria Test method: The test was carried out using human-derived strains belonging to the genus Streptococcus, Lactobacillus, Bifidobacterium, Clostridium, Staphylococcus, and Bacteroides. A PYF liquid medium was used for the Bacteroides genus, and 0.25% water-soluble polysaccharide was added aseptically to each medium. Each bacterial cell suspension was inoculated into the medium so that the number of bacteria was 10 5 to 10 6 and cultured anaerobically for 48 hours. Meanwhile, glucose 0.5% as a control
Each bacterial cell was cultured in the same manner using the supplemented medium and a sugar-free medium as a blind test. The fermentability of each bacterial cell is measured at 660nm of the glucose culture solution.
The value obtained by subtracting the blinded value from the absorbance value at
100, and the value obtained by subtracting the blind value from the absorbance value at 660 nm of each culture solution was converted and expressed.
【表】【table】
【表】【table】
【表】 試験結果： 表４に示すとおりである。【table】 Test results: As shown in Table 4.
【表】
上記試験結果から、本発明の有効成分であるヘ
ミセルロースＢがビフイドバクテリウム菌に選択
的に発酵されることがわかる。
以下実施例を示して本発明とその効果を具体的
に説明する。
実施例
ヘミセルロースＢの調製：
脱脂した米糠100ｇに0.5N水酸化ナトリウム溶
液１を加え、窒素ガスで置換した容器内で1130
ストローク／分、18時間で抽出した。この抽出液
を遠心分離（3000rpm，10分間）で残渣を除去
し、酢酸で中和した後、最終濃度７％になるよう
トリクロル酢酸を加えて除蛋白して上清を得た。
次に、限外濾過で脱塩し、上清の約４倍量のエタ
ノールを加えて水溶性多糖の沈澱を得た。
この沈澱物を水で溶解した後、凍結乾燥してヘ
ミセルロースB4ｇの粉末を得た。
なお、上記脱脂米糠に代えて小麦麸100ｇを用
いて同様に処理した場合にはヘミセルロースB6
ｇの粉末が得られた。
ヘミセルロースＢの整腸作用：
次に、上述のごとくして得られた米糠由来のヘ
ミセルロースＢの整腸作用を調べるために、下記
により動物試験を行つた。
盲腸内内容物のPH測定
体重約70ｇのSD系ラツト（日本クレア(株)製）
を対照飼料で７日間予備飼育した後、１群４匹ず
つ２群に分け、表５に示したごとくの実験飼料の
投与して、３週間飼育した。なお、飼料及び水は
自由に摂取させた。
盲腸内内容物のPHは、エーテル麻酔下で開腹し
て盲腸内内容物を取出し、PHメーターにより測定
した。
動物実験に用いた飼料の成分組成を表５に、飼
料投与後の盲腸内内容物のPHを表６に、腸内菌代
謝産物の有機酸量を表７にそれぞれ示す。[Table] The above test results show that hemicellulose B, which is the active ingredient of the present invention, is selectively fermented by Bifidobacterium. EXAMPLES The present invention and its effects will be specifically explained below with reference to Examples. Example Preparation of hemicellulose B: Add 0.5N sodium hydroxide solution 1 to 100 g of defatted rice bran, and heat to 1130 g in a container purged with nitrogen gas.
Extracted at strokes/min, 18 hours. This extract was centrifuged (3000 rpm, 10 minutes) to remove residues, neutralized with acetic acid, and then trichloroacetic acid was added to a final concentration of 7% to remove protein and obtain a supernatant.
Next, the mixture was desalted by ultrafiltration, and about 4 times the amount of ethanol as the supernatant was added to obtain a precipitate of water-soluble polysaccharide. This precipitate was dissolved in water and then lyophilized to obtain 4 g of hemicellulose B powder. In addition, when 100g of wheat bran is used in place of the above-mentioned defatted rice bran and treated in the same manner, hemicellulose B6
g of powder was obtained. Intestinal regulating action of hemicellulose B: Next, in order to investigate the intestinal regulating action of the rice bran-derived hemicellulose B obtained as described above, the following animal test was conducted. PH measurement of cecal contents SD rats weighing approximately 70 g (manufactured by Nippon Clea Co., Ltd.)
After being preliminarily fed with a control feed for 7 days, the mice were divided into 2 groups of 4 animals each, fed with the experimental feed shown in Table 5, and fed for 3 weeks. In addition, feed and water were available ad libitum. The PH of the cecal contents was measured using a PH meter after abdominal surgery was performed under ether anesthesia to remove the cecal contents. Table 5 shows the component composition of the feed used in the animal experiment, Table 6 shows the pH of the contents of the caecum after administration of the feed, and Table 7 shows the amount of organic acids in intestinal bacteria metabolites.
【表】【table】
【表】【table】
【表】【table】
【表】
表６に示す通り、米糠由来のヘミセルロースＢ
を投与することにより盲腸内のPHが低下し、又表
７に示す通り、ビフイドバクテリウム菌の代謝産
物である酢酸が産生され、従つて腐敗性細菌の繁
殖を抑制することが期待される。
糞中のビフイドバクテリウム菌数の測定：
実験期間中の０，１，２及び３週目毎に糞を採
取し、光岡の方法に従つてビフイドバクテリウム
菌数を測定した。結果は図に示すとおりである。
図にみられるとおり、米糠由来のヘミセルロース
Ｂ投与群では、１週目よりビフイドバクテリウム
菌数が顕著に増加することがわかる。[Table] As shown in Table 6, hemicellulose B derived from rice bran
By administering Bifidobacterium, the PH in the cecum decreases, and as shown in Table 7, acetic acid, which is a metabolite of Bifidobacterium, is produced, which is expected to suppress the growth of putrefactive bacteria. . Measurement of the number of Bifidobacterium bacteria in feces: Feces were collected every 0, 1, 2, and 3 weeks during the experimental period, and the number of Bifidobacterium bacteria was determined according to the method of Mitsuoka. The results are shown in the figure.
As seen in the figure, in the rice bran-derived hemicellulose B administration group, the number of Bifidobacterium bacteria increased significantly from the first week.
図は、米糠由来のヘミセルロースＢを添加した
飼料を投与したラツト群と、ヘミセルロースＢ無
添加の対照飼料を投与したラツト群の各糞中のビ
フイドバクテリウム菌数の経日変化を示したもの
である。
The figure shows the daily changes in the number of Bifidobacterium bacteria in each feces of a group of rats given a diet supplemented with hemicellulose B derived from rice bran and a group of rats given a control diet without hemicellulose B. It is.
Claims (1)
ロコシ外皮由来のものである特許請求の範囲１項
記載の整腸剤。[Claims] 1. An intestinal regulating agent containing hemicellulose B as an active ingredient. 2. The intestinal regulating agent according to claim 1, wherein hemicellulose B is derived from rice bran, wheat bran, or corn husk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61309240A JPS63165325A (en) | 1986-12-27 | 1986-12-27 | Intestine-conditioning agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61309240A JPS63165325A (en) | 1986-12-27 | 1986-12-27 | Intestine-conditioning agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63165325A JPS63165325A (en) | 1988-07-08 |
| JPH045649B2 true JPH045649B2 (en) | 1992-02-03 |
Family
ID=17990614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61309240A Granted JPS63165325A (en) | 1986-12-27 | 1986-12-27 | Intestine-conditioning agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63165325A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0611764B2 (en) * | 1988-12-07 | 1994-02-16 | 雪印乳業株式会社 | Method for producing water-soluble hemicellulose |
| JP3007645B2 (en) * | 1990-01-10 | 2000-02-07 | 日本食品化工株式会社 | Inhibitors of intestinal toxic enzymes |
| JP2787252B2 (en) * | 1991-06-17 | 1998-08-13 | 雪印乳業株式会社 | Colorectal cancer inhibitor |
| JP4698796B2 (en) * | 2000-05-15 | 2011-06-08 | 日本食品化工株式会社 | Immunostimulator |
| JP4499406B2 (en) * | 2003-12-19 | 2010-07-07 | 三井農林株式会社 | Intestinal function improving agent |
| JP2007222126A (en) * | 2006-02-27 | 2007-09-06 | Chikuno Shokuhin Kogyo Kk | Candy using deproteinized and defatted rice bran |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51142546A (en) * | 1975-04-09 | 1976-12-08 | Draco Ab | Intestines adjusting agent |
| JPS62205766A (en) * | 1986-03-04 | 1987-09-10 | Tanpei Seiyaku Kk | Fibrous food |
-
1986
- 1986-12-27 JP JP61309240A patent/JPS63165325A/en active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51142546A (en) * | 1975-04-09 | 1976-12-08 | Draco Ab | Intestines adjusting agent |
| JPS62205766A (en) * | 1986-03-04 | 1987-09-10 | Tanpei Seiyaku Kk | Fibrous food |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63165325A (en) | 1988-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tester et al. | Glucomannans and nutrition | |
| JP5701471B2 (en) | Plant-derived material with high indigestible content | |
| JP4071823B2 (en) | Fatty acid delivery system | |
| AU2008251346B2 (en) | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same | |
| JP2008504038A (en) | Pre-biological preparation | |
| JP2002223727A (en) | Functional food | |
| CN111066991A (en) | Preparation method of composite prebiotics solid beverage for improving gastrointestinal tract function | |
| JPH045649B2 (en) | ||
| US20120107449A1 (en) | Mineral-absorption promoter, food and feed | |
| JP5484913B2 (en) | Insoluble dietary fiber-containing substances derived from cereal plant seeds | |
| JP4054697B2 (en) | Constipation improving agent | |
| JPS62201821A (en) | Substance for suppressing hyperglycemia | |
| JP2011250716A (en) | Vitamin b1 composition with improved flavor, and method of suppressing flavor of vitamin b1 | |
| CN1060321C (en) | Food made from wheat bran with wall-broken cells and containing rich scytonemataceae and its production method | |
| JPH0434527B2 (en) | ||
| Delcour et al. | Wheat bran derived arabinoxylanoligosaccharides: a novel prebiotic concept? | |
| KR20030069231A (en) | The improvement product of intestianl function by means of constipation type | |
| AU695906B2 (en) | Fatty acid delivery system | |
| JPH0678236B2 (en) | Liver function activator | |
| JP6116174B2 (en) | Oral composition for improving bowel movements | |
| JP2024512375A (en) | Yeast glycoside inhibitors | |
| JPH07121867B2 (en) | Liver function activator | |
| CN116250636A (en) | Citrus prebiotic composition and preparation method and application thereof | |
| CN117044954A (en) | Dietary fiber functional flavor food and preparation method thereof | |
| JP2003047437A (en) | Processed food containing essence of fermented cabbage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |